TrialInternational journal of hematology2024

A prospective study of zanubrutinib, a Bruton tyrosine kinase inhibitor, in relapsed/refractory idiopathic multicentric Castleman disease.

Lu Zhang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.